Belatacept: A worthy alternative to cyclosporine?

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 1, 2012, Pages 90-92

  Melvin, George ^a   Sandhiya, Selvarajan ^a   Subraja, Kumaresan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; AMINO ACID SUBSTITUTION; ANEMIA; ARTICLE; BINDING AFFINITY; CHRONIC ALLOGRAFT NEPHROPATHY; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEART DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIGAND BINDING; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; URINARY TRACT INFECTION; VOMITING;

EID: 84878703506     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.92499     Document Type: Article

References (16)

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-30.
2. Cecka JM. The OPTN/UNOS renal transplant registry. Clin Transpl 2005. p. 1-16.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-33.
4. Krejci K, Tichy T, Bachleda P, Zadrazil J. Calcineurin inhibitor-induced renal allograft nephrotoxicity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 297-306.
5. Ducloux D, Motte G, Kribs M, Abdelfatah AB, Bresson-Vautrin C, Rebibou JM, et al. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 2002; 57: 409-13.
6. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-14.
7. Porrini E, Delgado P, Torres A. Metabolic syndrome, insulin resistance, and chronic allograft dysfunction. Kidney Int Suppl 2010; 119: S42-6.
8. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept): A high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-53.
9. Snanoudj R, Frangie C, Deroure B, Francois H, Creput C, Beaudreuil S, et al. The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept. Biologics 2007; 1: 203-13.
10. Wojciechowski D, Vincenti F. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Curr Opin Organ Transplant 2010; 15: 697-702.
11. Maryland: Belatacept (BMS-224818). Briefing document for FDA's cardiovascular and renal drugs advisory committee. 2011. Available from: http://www.fda.gov/downloads/advisorycommittees/drugs/ucm201859.pdf. [updated 2011 March; cited 2011 July 1].
12. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-46.
13. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-57.
14. Maryland: FDA approves Nulojix for kidney transplant patients. 2011; Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm259184.htm. [updated 2011 June 16; cited 2011 July 1].
15. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-62.
16. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-96.